- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04573023
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
March 3, 2024 updated by: JCR Pharmaceuticals Co., Ltd.
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: JCR Pharmaceuticals Co., Ltd.
- Phone Number: +81-(0)797-32-8582
- Email: clinical_development@jp.jcrpharm.com
Study Locations
-
-
-
Buenos Aires, Argentina
- Recruiting
- Hospital Universitario Austral
-
Contact:
- Hernán M Amartino
- Phone Number: +541158239252
-
-
-
-
-
Porto Alegre, Brazil
- Recruiting
- Hospital de Clinicas de Porto Alegre
-
Contact:
- Roberto Giugliani
-
Contact:
- Phone Number: +5551-3359-6340
-
Recife, Brazil
- Recruiting
- Instituto de Medicina Integral Prof. Fernando Figueira - Imip
-
Contact:
- Ana C Menezes
- Phone Number: +55 81 2122-4792
-
São Paulo, Brazil
- Recruiting
- Instituto de Genética e Erros Inatos do Metabolismo
-
Contact:
- Ana Maria Martins
-
Contact:
- Phone Number: +5511-5081-9620
-
-
-
-
-
Bron cedex, France
- Recruiting
- Hôpital Femme Mère Enfant
-
Contact:
- Nathalie Guffon
-
Contact:
- Phone Number: +33-825-08-25-69
-
Montpellier, France
- Recruiting
- Chu De Montpellier Hopital Gui De Chauliac
-
Contact:
- Agathe Roubertie
- Phone Number: +33 467 336733
-
Paris, France
- Recruiting
- Hopital Armand Trousseau
-
Contact:
- Benedicte Héron-Longe
- Phone Number: +33 1 44 73 74 75
-
-
-
-
-
Giessen, Germany
- Recruiting
- Universitätsklinikum Gießen
-
Contact:
- Christina Lampe
- Phone Number: +49 641 985 52908
-
Hamburg, Germany
- Recruiting
- Universitätsklinikum Hamburg-Eppendorf
-
Contact:
- Nichole Muschol
-
Contact:
- Phone Number: +49 40 74100
-
Hochheim, Germany
- Recruiting
- SphinCS GmbH
-
Contact:
- Eugen Mengel
-
Contact:
- Phone Number: +49-6146-904820
-
Mainz, Germany
- Recruiting
- Universitätsmedizin Mainz
-
Contact:
- Julia Hennermann
-
Contact:
- Phone Number: +49 6131 17 0
-
-
-
-
-
Rome, Italy
- Recruiting
- Osp. Pediatrico Bambino Gesù, IRCCS
-
Contact:
- Federica Deodato
- Phone Number: +39 668592275
-
-
-
-
-
Kraków, Poland
- Recruiting
- Uniwersytecki Szpital Dzieciecy
-
Contact:
- Przemk Kwinta
- Phone Number: 48126582011
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Hospital Sant Joan de Deu
-
Contact:
- Mar O'Callaghan
-
Contact:
- Phone Number: +34-93-600-97-83
-
-
-
-
-
Ankara, Turkey
- Recruiting
- Gazi University Medicine Faculty Hospital
-
Contact:
- Fatih S Ezgu
- Phone Number: +905372653249
-
-
-
-
-
London, United Kingdom
- Recruiting
- Great Ormond Street Hospital for Children NHS Trust - Metabolic Medicine
-
Contact:
- James Davison
- Phone Number: +44 20 7405 9200
-
-
-
-
California
-
Oakland, California, United States, 94609
- Recruiting
- UCSF Benioff Children's Hospital Oakland
-
Contact:
- Paul Harmatz
-
Contact:
- Phone Number: +1-510-428-3058
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Contact:
- Barbara Burton
-
Contact:
- Phone Number: 312-227-6120
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Chester B. Whitley
-
Contact:
- Phone Number: +1 612-625-1594
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7487
- Recruiting
- University of North Carolina at Chapel Hill Medical School Wing E
-
Contact:
- Elizabeth Jalazo, Dr.
- Phone Number: 919-962-8463
- Email: veronica_lippuner@med.unc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Can Ficicioglu
-
Contact:
- Phone Number: +1-800-879-2467
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- A patient who voluntarily signs an Institutional Review Board or Independent Ethics Committee-approved written informed consent form. If the patient is aged under 18 years (aged under 16 years in the UK) at the time of enrollment or willingness to participate in the study cannot be confirmed due to MPS II-related intellectual disability, the patient's legally acceptable representative (e.g., his/her parents or guardians) may sign the informed consent on behalf of the patient. Written informed assent should be obtained from the patient, wherever possible.
- Patients with confirmed diagnosis of MPS II
- Naïve patients or patients who are receiving stable enzyme replacement therapy with idursulfase for more than 12 weeks before starting administration of JR-141 or idursulfase for this study.
- Patients or patients whose partners are of child-bearing potential agree to use a medically accepted, highly effective method of contraception being use of condoms from the time of informed consent.
<Cohort A>
- Patients aged 36-42 months old at the time of ICF signing: patients must have a standard score measured by the BSID-III of 85 or less at screening.
- Patients aged 43-71 months old at the time of ICF signing: patients must EITHER have (1) A DQ measured by BSID-III of 20 to 85 at screening OR (2) A composite standard score on NVI measured by KABC-II of 85 or less at screening (only who can perform KABC-II)
- Patients aged 30-35 months old at the time of randomization and who are judged as having the severe phenotype by the Expert Board.
<Cohort B>
- Patients 6 years of age or older at the time of ICF signing and whose IQ are 70 and higher.
- Enrollment of subjects in Cohort B is contingent on the availability in that country of a validated country-specific version of the test (either WISC-V, WAIS-IV, or T.O.V.A.).
- Attenuated patients with 1 SD deficiency in the omission errors or variability domains of the T.O.V.A..
Exclusion Criteria:
- A patient with a history of HSCT with successful engraftment.
- A patient who has received gene therapy treatment at any point.
- Unable to undergo lumbar puncture.
- A patient who is enrolled in another clinical study that involves clinical investigations or use of any investigational product (drug or device) within 4 months before obtaining informed consent.
- Unable to comply with the protocol as determined by the principal investigator or subinvestigator.
- Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of serious drug allergy or sensitivity including anesthesia or hypersensitivity to any component of JR-141.
- A patient who has a known or suspected local or general infection or is at risk of abnormal bleeding due to medical conditions or therapies.
- A patient who has documented mutation of other genes, including loci adjacent to the IDS gene that are known to be associated with developmental delay, seizures, or other significant CNS disorders.
- A patient who has documented loss of activity of sulfatases other than IDS.
- A patient who has had a ventriculoperitoneal shunt placed or any other brain surgery, or has a clinically significant ventriculoperitoneal shunt malfunction within 30 days of screening.
- full time employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members.
- A patient who otherwise is judged by the principle investigator or sub-investigator to be ineligible to participate in the study.
[Only in France]
- Persons deprived of their liberty by a judicial or administrative decision, according to article L.1121-6 the Public Health Code (Code de la santé publique), adults who are the subject of a measure of legal protection or unable to express their consent according to article L. 1121-8 of the Code de la santé publique)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JR-141 2.0 mg/kg/week
|
IV infusion, 2.0 mg/kg/week
|
Other: administered as the standard of care: idursulfase (ELAPRASE®)
standard of care-controlled study
|
IV infusion
|
Other: Rescue arm
|
The subjects who have achieved the pre-specified criteria* are able to change the drug. *If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141. If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in levels of cerebrospinal fluid heparan sulfate from baseline (Cohort A)
Time Frame: Baseline to Week 53
|
Baseline to Week 53
|
Change in the raw scores of cognitive testing measured from baseline (BSID-III) (Cohort A)
Time Frame: Baseline to Week 105
|
Baseline to Week 105
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the growth scores of cognitive testing measured from baseline (BSID-III) (Cohort A)
Time Frame: Baseline to Week 105
|
Baseline to Week 105
|
Change in the age equivalent scores of adaptive behavior measured from baseline (VABS-II) (Cohort A)
Time Frame: Baseline to Week 105
|
Baseline to Week 105
|
Relative change in liver volume relative to body weight from baseline (Cohort A and Cohort B)
Time Frame: Baseline to Week 53
|
Baseline to Week 53
|
Relative change in spleen volume relative to body weight from baseline (Cohort A and Cohort B)
Time Frame: Baseline to Week 53
|
Baseline to Week 53
|
Relative change in distance walked using the 6-minute walk test from baseline to Week 53 (Cohort B)
Time Frame: Baseline to Week 53
|
Baseline to Week 53
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in levels of cerebrospinal fluid heparan sulfate from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 105
|
Baseline to Week 26, 105
|
|
Change in levels of cerebrospinal fluid dermatan sulfate from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 53, 105
|
Baseline to Week 26, 53, 105
|
|
Change in levels of cerebrospinal fluid heparan sulfate from baseine. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in levels of cerebrospinal fluid dermatan sulfate from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in adaptive behavioral testing measured from baseline
Time Frame: Baseline to Week 26, 53, 78, 105
|
Vineland Adaptive Behavior Scales (Cohort A)
|
Baseline to Week 26, 53, 78, 105
|
Change in adaptive behavioral testing measured from baseline
Time Frame: Baseline to Week 26, 53
|
Vineland Adaptive Behavior Scales (Cohort B)
|
Baseline to Week 26, 53
|
Change in cognitive testing measured from baseline
Time Frame: Baseline to Week 26, 53, 78, 105
|
BSID-III and KABC-II (Cohort A)
|
Baseline to Week 26, 53, 78, 105
|
Change in the standard scores on omission error and variability domain measured by T.O.V.A. or composite scores on Processing speed or Working Memory measured by WISC/WAIS from baseline (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in adaptive behavior measured by VABS-II, and intelligence scale measured by WISC/WAIS from baseline (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the Quality of Life by HS FOCUS from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the Quality of Life by PedsQL from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 53, 78, 105
|
Baseline to Week 26, 53, 78, 105
|
|
Change in the Quality of Life by PedsQL from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the Quality of Life by PedsQL-FIM from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 53, 78, 105
|
Baseline to Week 26, 53, 78, 105
|
|
Change in the Quality of Life by PedsQL-FIM from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the Quality of Life by CSHQ from baseline.(Cohort A)
Time Frame: Baseline to Week 26, 53, 78, 105
|
Baseline to Week 26, 53, 78, 105
|
|
Change in the Quality of Life by CSHQ from baseline.(Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the global impression of severity and change by CGI from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 53, 78, 105
|
Baseline to Week 26, 53, 78, 105
|
|
Change in the global impression of severity and change by CGI from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the global impression of severity and change by PGI from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 53, 78, 105
|
Baseline to Week 26, 53, 78, 105
|
|
Change in the global impression of severity and change by PGI from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the Toileting Abilities Survey from baseline. (Cohort A)
Time Frame: Baseline to Week 13, 26, 53, 78, 105
|
Baseline to Week 13, 26, 53, 78, 105
|
|
Change in the Toileting Abilities Survey from baseline. (Cohort B)
Time Frame: Baseline to Week 13, 26, 53
|
Baseline to Week 13, 26, 53
|
|
Change in Auditory Brainstem Response. (Cohort A)
Time Frame: Baseline to Week 26, 53, 105
|
Baseline to Week 26, 53, 105
|
|
Change in Auditory Brainstem Response. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in cerebrospinal fluid opening pressure. (Cohort A)
Time Frame: Baseline to Week 26, 53, 105
|
Baseline to Week 26, 53, 105
|
|
Change in cerebrospinal fluid opening pressure. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Relative change in liver volume relative to body weight from baseline (Cohort A)
Time Frame: Baseline to Week 26, 105
|
Baseline to Week 26, 105
|
|
Relative change in liver volume relative to body weight from baseline (Cohort B)
Time Frame: Baseline to Week 26
|
Baseline to Week 26
|
|
Relative change in spleen volume relative to body weight from baseline (Cohort A)
Time Frame: Baseline to Week 26, 105
|
Baseline to Week 26, 105
|
|
Relative change in spleen volume relative to body weight from baseline (Cohort B)
Time Frame: Baseline to Week 26
|
Baseline to Week 26
|
|
Relative change in distance walked using the 6-minute walk test from baseline (Cohort B)
Time Frame: Baseline to Week 26
|
Baseline to Week 26
|
|
Change in Joint Range of Motion by goniometer from baseline (Cohort A)
Time Frame: Baseline to Week 26, 53, 105
|
Baseline to Week 26, 53, 105
|
|
Change in Joint Range of Motion by goniometer from baseline (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Absolute change in the Forced Vital Capacity from baseline (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Absolute change in the Forced Expiratory Volume from baseline (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Absolute change in the percent predicted Forced Vital Capacity from baseline (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in levels of serum heparan sulfate from baseline (Cohort A)
Time Frame: Baseline to Week 13, 26, 53, 78, 105
|
Baseline to Week 13, 26, 53, 78, 105
|
|
Change in levels of serum heparan sulfate from baseline (Cohort B)
Time Frame: Baseline to Week 13, 26, 53
|
Baseline to Week 13, 26, 53
|
|
Change in levels of serum dermatan sulfate from baseline (Cohort A)
Time Frame: Baseline to Week 13, 26, 53, 78, 105
|
Baseline to Week 13, 26, 53, 78, 105
|
|
Change in levels of serum dermatan sulfate from baseline (Cohort B)
Time Frame: Baseline to Week 13, 26, 53
|
Baseline to Week 13, 26, 53
|
|
Change in levels of the urine heparan sulfate from baseline. (Cohort A)
Time Frame: Baseline to Week 13, 26, 53, 78, 105
|
Baseline to Week 13, 26, 53, 78, 105
|
|
Change in levels of the urine heparan sulfate from baseline. (Cohort B)
Time Frame: Baseline to Week 13, 26, 53
|
Baseline to Week 13, 26, 53
|
|
Change in levels of the urine dermatan sulfate from baseline. (Cohort A)
Time Frame: Baseline to Week 13, 26, 53, 78, 105
|
Baseline to Week 13, 26, 53, 78, 105
|
|
Change in levels of the urine dermatan sulfate from baseline. (Cohort B)
Time Frame: Baseline to Week 13, 26, 53
|
Baseline to Week 13, 26, 53
|
|
Change in the left ventricular mass index (LVMI) from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 53, 105
|
Baseline to Week 26, 53, 105
|
|
Change in LVMI from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the interventricular septum thickness (IVST) from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 53, 105
|
Baseline to Week 26, 53, 105
|
|
Change in IVST from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Change in the posterior wall thickness (PWT) from baseline. (Cohort A)
Time Frame: Baseline to Week 26, 53, 105
|
Baseline to Week 26, 53, 105
|
|
Change in PWT from baseline. (Cohort B)
Time Frame: Baseline to Week 26, 53
|
Baseline to Week 26, 53
|
|
Growth velocity (Cohort A)
Time Frame: Week 53, 105
|
Week 53, 105
|
|
Growth velocity (Cohort B)
Time Frame: Week 53
|
Week 53
|
|
Ongoing assessment of adverse events.
Time Frame: Through study period
|
adverse drug reactions (Cohort A and Cohort B)
|
Through study period
|
Antibodies
Time Frame: Baseline, Week 105
|
Plasma: Anti-IDS antibody (Cohort A)
|
Baseline, Week 105
|
Antibodies
Time Frame: Baseline, Week 53
|
Plasma: Anti-IDS antibody (Cohort B)
|
Baseline, Week 53
|
Antibodies
Time Frame: Baseline, Week 5, 13, 26, 53, 78,105
|
Plasma: Anti-JR-141 antibody (Cohort A)
|
Baseline, Week 5, 13, 26, 53, 78,105
|
Antibodies
Time Frame: Baseline, Week 5, 13, 26, 53
|
Plasma: Anti-JR-141 antibody (Cohort B)
|
Baseline, Week 5, 13, 26, 53
|
Antibodies
Time Frame: Baseline, Week 26, 53, 105
|
Cerebrospinal fluid: Anti-JR-141 antibody (Cohort A)
|
Baseline, Week 26, 53, 105
|
Antibodies
Time Frame: Baseline, Week 26, 53
|
Cerebrospinal fluid: Anti-JR-141 antibody (Cohort B)
|
Baseline, Week 26, 53
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 14, 2022
Primary Completion (Estimated)
January 31, 2026
Study Completion (Estimated)
January 31, 2026
Study Registration Dates
First Submitted
September 17, 2020
First Submitted That Met QC Criteria
September 25, 2020
First Posted (Actual)
October 5, 2020
Study Record Updates
Last Update Posted (Estimated)
March 5, 2024
Last Update Submitted That Met QC Criteria
March 3, 2024
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Connective Tissue Diseases
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Mucopolysaccharidosis II
- Mucopolysaccharidoses
Other Study ID Numbers
- JR-141-GS31
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mucopolysaccharidosis II
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedKrabbe Disease | Mucopolysaccharidosis Type II (MPS II) | Mucopolysaccharidosis Type I (MPS I) | Mucopolysaccharidosis Type III (MPS III) | Mucopolysaccharidosis Type VI (MPS VI)United States
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VI | Mucopolysaccharidosis Type IV | Mucopolysaccharidosis Type VIIUnited States, Canada
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Brazil
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Canada
-
Lundquist Institute for Biomedical Innovation at...CompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VIUnited States
-
University Hospital HeidelbergCompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Coping Behavior | Mucopolysaccharidosis Type III | Behavior DisordersGermany
-
TakedaCompletedMucopolysaccharidosis (MPS)Brazil
-
JCR Pharmaceuticals Co., Ltd.Active, not recruitingMucopolysaccharidosis IIJapan
-
JCR Pharmaceuticals Co., Ltd.Completed
-
Denali Therapeutics Inc.RecruitingMucopolysaccharidosis IIUnited States, Spain, United Kingdom, Czechia, France, Canada, Italy, Belgium, Netherlands, Germany, Argentina, Sweden, Turkey, Colombia
Clinical Trials on JR-141
-
JCR Pharmaceuticals Co., Ltd.Active, not recruitingMucopolysaccharidosis IIJapan
-
JCR Pharmaceuticals Co., Ltd.Completed
-
JCR Pharmaceuticals Co., Ltd.Completed
-
JCR Pharmaceuticals Co., Ltd.Active, not recruitingMucopolysaccharidosis IIBrazil
-
JCR Pharmaceuticals Co., Ltd.Enrolling by invitationMucopolysaccharidosis IIUnited States
-
JCR Pharmaceuticals Co., Ltd.Completed
-
AbbVieRecruiting
-
TetraLogic PharmaceuticalsPPD; The Leukemia and Lymphoma Society; Veristat, Inc.; Therapeutics, Inc.CompletedLymphoma, T-Cell, CutaneousUnited States
-
JCR Pharmaceuticals Co., Ltd.Active, not recruitingMucopolysaccharidosis IUnited States, Brazil, Japan
-
JCR Pharmaceuticals Co., Ltd.RecruitingMucopolysaccharidosis III-AGermany